Company / R&D Expense
Cartesian Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$45.1M
FY2025
5-year range
$42.7M / $71.3M
FY2021-FY2025
Trend
-36.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $10M in FY2016 to $71M in FY2024.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -1.1%.
Declined from $69M to $45M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -6.1%
- 5-Year CAGR
- -1.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 36.7% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.1M | -36.7% |
| FY2024 | $71.3M | +3.7% |
| FY2023 | $68.7M | +26.1% |
| FY2022 | $54.5M | +27.5% |
| FY2021 | $42.7M | -10.4% |
| FY2020 | $47.7M | +5.6% |
| FY2019 | $45.2M | +330.7% |
| FY2016 | $10.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026